A Novel Liver Targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men with Prostate Cancer - A Blinded Randomized Controlled Trial
Phase 2
Recruiting
- Conditions
- Prostate CancerSarcopeniaAndrogen Deprivation TherapyMetabolic and Endocrine - Other metabolic disordersCancer - ProstateMusculoskeletal - Other muscular and skeletal disorders
- Registration Number
- ACTRN12616001166460
- Lead Sponsor
- Metro South Health and Hospital Service
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
All men with prostate cancer on Androgen Deprivation therapy
- no time limit regarding diagnosis
Exclusion Criteria
50% increase in PSA or increase in PSA to >4nmol/L above baseline after commencement of intervention
Previous Thyroid Dysfunction
Serious adverse event caused by product
Participants decision to withdrawl
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Molecular mechanism liver-targeted testosterone therapy sarcopenia androgen deprivation prostate cancer muscle selectivity
Comparative effectiveness liver-targeted testosterone versus exercise nutrition sarcopenia ADT prostate cancer
Predictive biomarkers testosterone response sarcopenia androgen deprivation therapy prostate cancer progression risk
Safety profile liver-targeted testosterone therapy prostate cancer ADT PSA cardiovascular liver function
SARMs versus novel testosterone formulations sarcopenia management androgen deprivation prostate cancer outcomes